{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T14:30:15Z","timestamp":1747233015797,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":20,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071627716"},{"type":"electronic","value":"9781071627723"}],"license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2772-3_6","type":"book-chapter","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:07:03Z","timestamp":1668794823000},"page":"107-124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Restoring Dystrophin Expression by Skipping Exons 6 and 8 in Neonatal Dystrophic Dogs"],"prefix":"10.1007","author":[{"given":"Md Nur Ahad","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6","journal-title":"Lancet Neurol"},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell JR, Shilling C, Leslie ND et al (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:304\u2013313","journal-title":"Ann Neurol"},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nrg1180","volume":"4","author":"JC Van Deutekom","year":"2003","unstructured":"Van Deutekom JC, Van Ommen G-JB (2003) Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 4:774\u2013783","journal-title":"Nat Rev Genet"},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbadis.2006.05.010","volume":"1772","author":"JM Ervasti","year":"2007","unstructured":"Ervasti JM (2007) Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta 1772:108\u2013117","journal-title":"Biochim Biophys Acta"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","volume":"32","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM (2014) Duchenne and Becker muscular dystrophies. Neurol Clin 32:671\u2013688","journal-title":"Neurol Clin"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci 102:198\u2013203","journal-title":"Proc Natl Acad Sci"},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu Q, Partridge T et al (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65:667\u2013676","journal-title":"Ann Neurol"},{"key":"6_CR8","first-page":"179","volume":"26","author":"T Yokota","year":"2007","unstructured":"Yokota T, Duddy W, Partridge T (2007) Optimizing exon skipping therapies for DMD. Acta Myol 26:179","journal-title":"Acta Myol"},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/1389201043376706","volume":"5","author":"V Arora","year":"2004","unstructured":"Arora V, Devi GR, Iversen PL (2004) Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol 5:431\u2013439","journal-title":"Curr Pharm Biotechnol"},{"issue":"13","key":"6_CR10","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7(13):1631\u20131635. https:\/\/doi.org\/10.4155\/fmc.15.116","journal-title":"Future Med Chem"},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/15476286.2021.1874161","volume":"18","author":"B Hanson","year":"2021","unstructured":"Hanson B, Wood MJA, Roberts TC (2021) Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. RNA Biol 18:1048\u20131062. https:\/\/doi.org\/10.1080\/15476286.2021.1874161","journal-title":"RNA Biol"},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M (2021) Casimersen: first approval. Drugs 81:1\u20135","journal-title":"Drugs"},{"key":"6_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-150113","volume":"3","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Fukada S-I, Yokota T (2016) Current translational research and murine models for Duchenne muscular dystrophy. J Neuromuscul Dis 3:29\u201348. https:\/\/doi.org\/10.3233\/JND-150113","journal-title":"J Neuromuscul Dis"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0888-7543(92)90210-j","volume":"13","author":"NJ Sharp","year":"1992","unstructured":"Sharp NJ, Kornegay JN, Van Camp SD et al (1992) An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13:115\u2013121. https:\/\/doi.org\/10.1016\/0888-7543(92)90210-j","journal-title":"Genomics"},{"key":"6_CR15","first-page":"1314","volume":"7","author":"X Yu","year":"2015","unstructured":"Yu X, Bao B, Echigoya Y, Yokota T (2015) Dystrophin-deficient large animal models: translational research and exon skipping. Am J Transl Res 7:1314\u20131331","journal-title":"Am J Transl Res"},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymthe.2018.10.011","volume":"27","author":"KRQ Lim","year":"2019","unstructured":"Lim KRQ, Echigoya Y, Nagata T et al (2019) Efficacy of multi-exon skipping treatment in Duchenne muscular dystrophy dog model neonates. Mol Ther 27:76\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2018.10.011","journal-title":"Mol Ther"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-6817-6_17","volume-title":"Morpholino oligomers","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Caluseriu O et al (2017) Systemic delivery of morpholinos to skip multiple exons in a dog model of Duchenne muscular dystrophy. In: Morpholino oligomers. Springer, pp 201\u2013213"},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-4939-8651-4_16","volume-title":"Exon skipping and inclusion therapies","author":"D Melo","year":"2018","unstructured":"Melo D, Maruyama R, Yokota T (2018) Systemic injection of peptide-PMOs into humanized DMD mice and evaluation by RT-PCR and ELISA. In: Exon skipping and inclusion therapies. Springer, pp 263\u2013273"},{"key":"6_CR19","doi-asserted-by":"publisher","unstructured":"Miskew Nichols B, Aoki Y, Kuraoka M et al (2016) Multi-exon skipping using cocktail antisense oligonucleotides in the canine X-linked muscular dystrophy. J Vis Exp:53776. https:\/\/doi.org\/10.3791\/53776","DOI":"10.3791\/53776"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Yokota T, Nagata T et al (2012) Bodywide skipping of exons 45\u201355 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci 109:13763\u201313768","journal-title":"Proc Natl Acad Sci"}],"container-title":["Methods in Molecular Biology","Muscular Dystrophy Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2772-3_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:07:27Z","timestamp":1677654447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2772-3_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"ISBN":["9781071627716","9781071627723"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_6","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"19 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}